Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1249-1259

  Gallagher, Katherine A ^a   Liu, Zhao Jun ^a   Xiao, Min ^a   Chen, Haiying ^a   Goldstein, Lee J ^a   Buerk, Donald G ^b   Nedeau, April ^a   Thom, Stephen R ^b   Velazquez, Omaida C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPHANE INSULIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL HOMING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HYPERBARIC OXYGEN; HYPEROXIA; ISCHEMIA; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN INJURY; STEM CELL; STEM CELL MOBILIZATION; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, CXC; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIAL CELLS; HYPEROXIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; PHOSPHORYLATION; STEM CELLS; WOUND HEALING;

EID: 34248213008     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29710     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention. 1998. Diabetes-related amputations of lower extremities in the Medicare population - Minnesota, 1993-1995. MMWR Morb. Mortal. Wkly. Rep. 47:649-652.
2. Feener, E.P., and King, G.L. 1997. Vascular dysfunction in diabetes mellitus. Lancet. 350(Suppl. 1):SI9-SI13.
3. Phillips, T.J. 1994. Chronic cutaneous ulcers: etiology and epidemiology. J. Invest. Dermatol. 102:38S-41S.
4. Hanahan, D. 1997. Signaling vascular morphogenesis and maintenance. Science. 277:48-50.
5. Carmeliet, P. 2000. Developmental biology. One cell, two fates. Nature. 408:43, 45.
6. Tepper, O.M., et al. 2005. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood. 105:1068-1077.
7. Rafii, S., and Lyden, D. 2003. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9:702-712.
8. Yamaguchi, J., et al. 2003. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 107:1322-1328.
9. Asahara, T., et al. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964-967.
10. Kawamoto, A., et al. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 103:634-637.
11. Takahashi, T., et al. 1999. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5:434-438.
12. Gill, M., et al. 2001. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88:167-174.
13. Aicher, A., et al. 2003. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9:1370-1376.
14. Murohara, T., et al. 1998. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101:2567-2578.
15. Ceradini, D.J., et al. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10:858-864.
16. Bivalacqua, T.J., et al. 2004. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. U. S. A. 101:9121-9126.
17. Bucci, M., et al. 2004. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler. Thromb. Vasc. Biol. 24:721-726.
18. Du, X.L., et al. 2001. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108:1341-1348. doi:10.1172/JCI200111235.
19. Szabo, C., et al. 2002. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation. 106:2680-2686.
20. Du, X., et al. 2006. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 116:1071-1080. doi:10.1172/JCI23354.
21. Thom, S.R., et al. 2002. Stimulation of nitric oxide synthase in cerebral cortex due to elevated partial pressures of oxygen: an oxidative stress response. J. Neurobiol. 51:85-100.
22. Thom, S.R., et al. 2003. Stimulation of perivascular nitric oxide synthesis by oxygen. Am. J. Physiol. Heart Circ. Physiol. 284:H1230-H1239.
23. Goldstein, L.J., et al. 2006. Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide. Stem Cells. 24:2309-2318.
24. Kessler, L., et al. 2003. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 26:2378-2382.
25. Kranke, P., Bennett, M., Roeckl-Wiedmann, I., and Debus, S. 2004. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst. Rev. 2:CD004123.
26. Abidia, A., et al. 2003. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur. J. Vasc. Endovasc. Surg. 25:513-518.
27. Fedyk, E.R., Ryyan, D.H., Ritterman, I., and Springer, T.A. 1999. Maturation decreases responsiveness of human bone marrow B lineage cells to stromalderived factor 1 (SDF-1). J. Leukoc. Biol. 66:667-673.
28. Tepper, O.M., et al. 2002. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 106:2781-2786.
29. Vasa, M., et al. 2001. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89:E1-E7.
30. Fadini, G.P., et al. 2005. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45:1449-1457.
31. Rafii, S., et al. 2003. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann. N. Y. Acad. Sci. 996:49-60.
32. Llevadot, J., et al. 2001. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108:399-405. doi:10.1172/JCI200113131.
33. Verma, S., et al. 2004. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 109:2058-2067.
34. Mohle, R., Rafii, S., and Moore, M.A. 1998. The role of endothelium in the regulation of hematopoietic stem cell migration. Stem Cells. 16(Suppl. 1):159-165.
35. + cells on vascular endothelium under shear flow. J. Clin. Invest. 104:1199-1211.
36. Lee, R.H., et al. 2006. A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood. 107:2153- 2161.
37. Miller, J.T., et al. 2005. The neuroblast and angioblast chemotaxic factor SDF-1 (CXCL12) expression is briefly up regulated by reactive astrocytes in brain following neonatal hypoxic-ischemic injury. BMC Neurosci. 6:63.
38. Urbich, C., et al. 2005. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39:733-742.
39. Keswani, S.G., et al. 2004. Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen. 12:497-504.
40. Bauer, S.M., et al. 2006. The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia. J. Vasc. Surg. 43:134-141.
41. Musicki, B., Kramer, M.F., Becker, R.E., and Burnett, A.L. 2005. Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. U. S. A. 102:11870-11875.
42. Powell, T.M., et al. 2005. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 25:296-301.
43. Kang, H.J., et al. 2004. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 363:751-756.
44. Morimoto, A., Sakata, Y., Watanabe, T., and Murakami, N. 1990. Leucocytosis induced in rabbits by intravenous or central injection of granulocyte colony stimulating factor. J. Physiol. 426:117-126.
45. Sheikh, A.Y., et al. 2000. Effect of hyperoxia on vascular endothelial growth factor levels in a wound model. Arch. Surg. 135:1293-1297.
46. Sen, C.K., et al. 2002. Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. Ann. N. Y. Acad. Sci. 957:239-249.
47. Peled, A., et al. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:845-848.
48. Sato, T.N., Qin, Y., Kozak, C.A., and Audus, K.L. 1993. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc. Natl. Acad. Sci. U. S. A. 90:9355-9358.
49. Schlaeger, T.M., et al. 1997. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 94:3058-3063.
50. Park, L., et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1025-1031.
51. Sheffield, P.J. 2004. How the Davis 2.36 ATA wound healing enhancement treatment table was established. Undersea Hyperb. Med. 31:193-194.
52. Buerk, D.G., Atochin, D.N., and Riva, C.E. 1998. Simultaneous tissue PO2, nitric oxide, and laser Doppler blood flow measurements during neuronal activation of optic nerve. Adv. Exp. Med. Biol. 454:159-164.
53. Kashiwagi, S., et al. 2005. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115:1816-1827. doi:10.1172/JCI24015.